Stay updated on KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial
Sign up to get notified when there's something new on the KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial page.

Latest updates to the KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial page
- Check7 days agoChange DetectedRevision: v3.3.1 is now displayed, replacing the previous v3.2.0.SummaryDifference0.2%

- Check14 days agoChange DetectedThe funding-status warning banner about government funding lapses was removed. The page continues to present the study details and locations.SummaryDifference0.2%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedCore study details appear unchanged. The visible updates seem to be routine metadata like the study location list and the update timestamp.SummaryDifference0.2%

- Check57 days agoChange DetectedIntroducing a government-funded status notice and a version upgrade to v3.2.0, replacing v3.0.2.SummaryDifference3%

- Check64 days agoChange DetectedCore content removing MedlinePlus drug safety topics and related MeSH terms; overall narrowing of drug-safety coverage.SummaryDifference0.7%

- Check71 days agoChange DetectedMinor formatting/localization update: adds a Mexican spelling/locale variant (México, Mexico, 03100) and removes the generic variant (Mexico, Mexico, 03100) and the Back to Top link.SummaryDifference0.2%

Stay in the know with updates to KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial page.